100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes
Immunotherapy Advances · 01.01.2021 · 1 (1)
DOI: 10.1093/immadv/ltab024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 24.11.2021. Verfasst von James A Pearson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Group, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Medical Research Council Career Development Award.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for people with T1D, preventing this from being a fatal condition. As we celebrate the centenary of this milestone, therapeutic options for T1D are once more at a turning point. Years of effort directed at developing immunotherapies are finally starting to pay off, with signs of progress in new onset and even preventative settings. Here, we review a selection of immunotherapies that have shown promise in preserving β cell function and highlight future considerations for immunotherapy in the T1D setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diabetes Research Group, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge, England, UK.
- Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, England, UK.
- Cambridge Centre for Artificial Intelligence in Medicine, University of Cambridge, Cambridge, England, UK.
- Division of Infection and Immunity, Institute or Immunity and Transplantation, University College London, Royal Free Campus, London, UK.
ORCID-Profile: James A Pearson
Förderung
- Wellcome Trust
- Medical Research Council
- Medical Research Council Career Development Award
- JDRF UK
- Diabetes UK
Zitieren
APA
Pearson, J. A., McKinney, E. F., & Walker, L. S. K. (2021). 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes. Immunotherapy Advances, 1(1). https://doi.org/10.1093/immadv/ltab024
Vancouver
Pearson JA, McKinney EF, Walker LSK. 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes. Immunotherapy Advances. 2021;1(1). doi:10.1093/immadv/ltab024
BibTeX
@article{Pearson2021,
author = {Pearson, James A and McKinney, Eoin F and Walker, Lucy S K},
title = {100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes},
journal = {Immunotherapy Advances},
year = {2021},
volume = {1},
number = {1},
doi = {10.1093/immadv/ltab024}
}
EUVIMED